6 February 2019 in Brain and Behavior
Introduction: The applicability of “Rubidium Chloride, 82 Rb from Generator” radiopharmaceutical for brain tumors (BT) diagnostics is demonstrated on the basis of the application experience of the radiopharmaceutical in neurooncology. Experimental: A total of 21 patients with various brain tumors and nonneoplastic abnormal brain masses were investigated. Results and Discussions: The results of the imaging and differential diagnostics of malignant and benign tumors, nonneoplastic abnormal brain masses and lesions revealed the prevalence of high uptake of the radiopharmaceutical in the malignant tumors in comparison with benign glioma and arteriovenous malformations in which 82 Rb‐chloride accumulates in the vascular phase but does not linger further. The ultra‐short half‐life of radionuclide 82 Rb (76 s) along with a low absorbed radiation dose with 82 Rb‐chloride by intravenous administration create a new possibility of successive use of two or more radiopharmaceuticals for the examination of the same patient. For instance, PET examination with 18 F‐FDG, 11 C‐methionine, 11 C‐choline, or any other radiopharmaceutical can be carried out in just 7–15 min. after 82 Rb‐chloride injection. Conclusion: Research demonstrated an effectiveness of 82 Rb‐chloride application as a diagnostic agent in neurooncology. A method of dosing and administration of the generator‐produced radiopharmaceutical has been worked out. It is possible to do up to 600 PET sessions using one Russian 82 Rb generator GR‐01. The generator is proved to be reliable and easy to use. The interest in 82 Rb‐chloride as a tumor‐seeking radiopharmaceutical rose due to the active application of the modern devices PET/CT in the routine clinical practice.
26 June 2023 in Radiatsionnaya Gygiena = Radiation Hygiene
Current patient release criteria established in NRB-99/2009 relate to four radionuclides used in Russia that period of the document preparation. These criteria were calculated only considering the radionuclide decay. Thus, these criteria give conservative assessments which require the patient to stay in dedicated protected room (“hot” room) of the radiotherapy department for several days and do not allow to radionuclide therapy to be given in the outpatient hospital which certainly reduces the availability of this type of treatment. Consideration of the biological excretion of the radiopharmaceutical will be able to make the patient release criteria after radionuclide therapy significantly softer. Recently, new promising radionuclides and radiopharmaceuticals for therapy have appeared, the introduction of which into medical practice is obstructed by the lack of the patient release criteria. Current study is devoted to justification of improvement the approach to definition of patient release criteria after radionuclide therapy with promising and applied radiopharmaceuticals considering biological excretion of radiopharmaceutical. As examples, calculations of patient release criteria were performed for 177Lu-PSMA, 177Lu-DOTA-TATE, 131I-mIBG и Na131I. The dosimetric model used for calculation is based on the model which was used for definition of the current patient release criteria in NRB-99/2009. Additionally, the biological excretion of the radionuclide in radiopharmaceutical, which was assessed according to the published data, was considered. Two phases of biological excretion were evaluated for considered radiopharmaceuticals (fast and slow fractions). The main contribution of the radionuclide decrease in the patient’s body during the first hours after the injection is made by the fast-eliminated fraction. During 4-6 hours after the administration about 50% of these radiopharmaceuticals eliminated via urine. The calculation of patient release criteria were performed for slow-elimination fractions which characterize the decrease of radionuclide activity in the body after the patient release. The following effective half-lives were used: 177Lu-PSMA – 60 hours, 177Lu-DOTA-TATE – 100 hours, 131I-mIBG – 45 hours, Na131I – 7.5 days. The calculations demonstrate when planning a course of radionuclide therapy with four administrations of 177Lu-PSMA, the release of a patient is allowed at the dose rate of 20 μSv/h from the patient at the distance of 1 m; in case of radionuclide therapy with 177Lu-DOTA-TATE, release of a patient is allowed at the dose rate of 12 μSv/h. Considering the fast-eliminated fraction in the first hours after the administration, it can be assumed that more patients with normal renal function can undergo radionuclide therapy with 177Lu-PSMA in the outpatient hospital. Some patients after the 177Lu-PSMA administration and patients in the therapy with 177Lu-DOTA-TATE may be held in the department in the “hot” rooms for 1-2 days until the dose rate decrease to the acceptable levels. The consideration of biological excretion of radiopharmaceutical makes it possible to soften patient release criterion for 131I-mIBG by four times and for Na131I – by 10%. It will allow to release patients after radionuclide therapy earlier without reduce of radiation safety of people around the patient and will increase the capacity of radionuclide therapy department.
17 January 2023 in Diagnostic radiology and radiotherapy
At the present time three most common approaches are used for the planning of the radionuclide therapy: administration of the fixed activity of radionuclide in radiopharmaceutical, or administration of activity normalized per unit of body mass or body surface. That may lead to significant deviations between the prescribed and real absorbed doses in healthy organs and tissues. These deviations are associated with differences in biodistribution and pharmacokinetics of radiopharmaceutical between models and real patients. That does not allow individual planning of the treatment course for each patient since data on the accumulated activity in source regions and organs at risk is limited and uncertainty is too high for the calculation of absorbed doses. Improvements in the reliability of the absorbed dose calculation can be achieved through the use of different imaging modalities (diagnostic nuclear medicine) for the quantitative assessment of accumulated activity of radionuclides in organs and tissues and distribution of radiopharmaceutical in healthy tissues. Planning of radionuclide therapy should be personalized. The current study was aimed at the analysis of the approaches the dosimetry-based planning of radionuclide therapy presented in the Report of International Commission on Radiation Units and Measurements 96 «Dosimetry-guided radiopharmaceutical therapy», differentiated based on the possibilities of the nuclear medicine departments, including examples of levels of planning for most common radiopharmaceuticals. The results of analysis indicated that most optimal approach for Russian clinical practice is to transit to the requirements of planning level 1: to calculate and report administered activity considering patient body mass, type and stage of disease was well as prescribed clinical task. Requirements of planning level 2 are currently impossible to implement nation-wide, except for several nuclear medicine research facilities. Additionally, it is necessary to focus on the development of the methods of estimation of absorbed doses in major delineable organs.
1 April 2018 in Voprosy onkologii
There is presented the review of domestic and foreign publications on cardiovascular complications in cancer patients at the stage of chemoradiation therapy. Cardiovascular сomplications due to cardiotoxicity are among the most severe side effects of anticancer therapy despite improved prognosis and survival of cancer patients. Modern treatment of cancer patients at the stage of chemotherapy and radiotherapy requires a multidisciplinary approach involving cardiologists and physicians of related specialties
17 January 2023 in Diagnostic radiology and radiotherapy
INTRODUCTION: Peptide receptor therapy based on the 225Ac radionuclide, due to the targeted effect on tumor cells, is the most promising method of treatment for patients with generalized forms of neuroendocrine tumors and castration-resistant prostate cancer.OBJECTIVE: The aim of the work was to evaluate the effectiveness of radioligand therapy of medicinal radiopharmaceuticals with 225Ac.MATERIALS AND METHODS: Radioligand therapy based on 225Ac radionuclide was performed in 7 patients with generalized prostate cancer and 3 patients with neuroendocrine tumors.RESULTS: Systemic radiation therapy with 225Ac-PSMA 617 and 225Ac-DOTATE showed its effectiveness in clinical practice — patients have a decrease in the level of accumulation of the radiopharmaceutical (RP) in pathological foci on PET-CT with 68Ga-PSMA and 68Ga-DOTATE; a decrease in the level of prostate-specific antigen (PSA) in the blood (for prostate cancer); reduction of manifestations of asthenic, pain and carcinoid (for neuroendocrine tumors) syndromes. Dosimetric studies make it possible to assess the biodistribution of a radiopharmaceutical drug in the body, accumulation in target organs and lesions.CONCLUSION: The appointment of this type of treatment requires an integrated approach based on a thorough study of medical records, assessment of the receptor status of the tumor tissue, timely detection and prediction of adverse reactions.
6 October 2024 in Radiatsionnaya Gygiena = Radiation Hygiene
Biological excretion from patients (urine) generated during radionuclide diagnostics enters directly into the hospital sewage system. The establishment of new clearance level according to Resolution of the Government of the Russian Federation No. 1069 of October 19, 2012 may entail amendments to regulatory documents for radionuclide diagnostics departments. One of these requirements is a mandatory dedicated sewage system. Establishment of the requirement may lead to an increase the cost of the radionuclide diagnostic examinations, and to a decrease the accessibility of radionuclide diagnostic. The aim of this study was to estimate the activity of radionuclides in patient urine after radionuclide diagnostic and activity concentration in sewage water in the hospital and in the transport tank of toilet for evaluation of paths of waste manage. Based on published literature data, models of biological excretion were constructed for the following radiopharmaceuticals: 99mTc-pyrophosphate, 64Cu-Labeled Monoclonal Antibody, 18F-FDG, 68Ga-PSMA-617. The activity of radionuclides in the patient waste in the hospital and in public transport during the patient transportation to home was calculated. Various scenarios of patient transportation were considered. The values of the excreted activity, activity concentration and dose rate at 1 m from the tank with sewage water for each type of transport were calculated. The calculated values of the radionuclide activity concentration in sewage water in transport tank of toilet for the majority scenarios exceed the clearance level (up to 180 times for 68Ga-PSMA-617 when traveling by bus). According the regulatory requirements, it is necessary to collect patient excretions after radionuclide diagnostic examinations and hold it for decay. However, estimated effective doses of individuals from the public from contact with biological patient waste do not exceed the acceptable value. This is due to the short half-life of diagnostic radionuclides. The paths of management system of biological patient waste were proposed.